BioCryst Pharmaceuticals, Inc.

Contributing Author

Recent Articles by BioCryst Pharmaceuticals, Inc.

May-30	BioCryst Highlights Real-world Data Showing ORLADEYO (berotralstat) Consistently Reduces HAE Attacks Across All Ages BCRX GlobeNewswire
May-27	BioCryst to Present at Upcoming Investor Conferences BCRX GlobeNewswire
May-16	BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO (berotralstat) BCRX GlobeNewswire
May-14	BioCryst Announces FDA Acceptance of NDA for ORLADEYO (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years BCRX GlobeNewswire
May-05	BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update BCRX GlobeNewswire
May-02	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire